NPCE management cites FDA approval potential for IGE expansion
NPCE management is optimistic about FDA approval for IGE, saying it could expand the addressable market by 20%. It also cites 21% core business growth and investments in sales, marketing and digital tools.
Management said it is optimistic about FDA approval for IGE, which could expand the addressable market by 20%. Core business is growing at 21%, with investments in sales, marketing and digital tools such as ECoG Assistant supporting adoption. Cash flow breakeven is targeted for 2027, with further growth expected.